drugset / Trial / NCT06365918
Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis
NaSingle-groupOpen-labelTreatment
Summary
To find the recommended dose of the investigational drug VG2025 that can be given intraperitoneally (given directly into the abdominal cavity) to participants with advanced solid tumors.
Timeline
- Start
- 2024-09-30
- Primary completion
- 2024-10-02
- Completion
- 2024-10-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VG2025 | Unknown | — | Other |